Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications[E8]

Uit de aankondiging

Call: Cluster 1 - Health (Single stage - 2027/1). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: Patients benefit from decreased incidence of Adverse Drug Reactions (ADRs) caused by the administration of multiple medications (three or more medicinal products [1] ) and enhanced health outcomes by ensuring safer and more effective use of medication. Healthcare professionals can adopt adverse drug reactions prevention and reduction strategies to integrate genetic and other biomarker information into clinical decision-making to optimise the use of medication, especially in situations of comorbidities. Healthcare systems benefit from cost savings thanks to reduced hospital admissions and other costs associated with ADRs related to the intake of multiple medicines. Clinical and regulatory guidelines and policies for medication management in case of multiple medications can be revised supported by robust evidence. Educational programs for healthcare providers and patients benefit from improved awareness and management of polypharmacy and ADRs. Scope: While medicinal products contribute considerably to the health of EU citizens, they can also have adverse reactions. It is estimated that ar…[E3]

De gegevens van de aankondiging staan zoals de bron ze publiceerde. De feiten en eisen die wij eruit halen zijn in het Engels.

• Open voorUniversities and research. Door SLETOR ingedeeld op basis van de woorden in de vermelding.
• VoorwaardeEU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]

• RisicoThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
• OnbekendWe read the funder's listing, not the full guidance or application forms.

1. Open voor inschrijving · 29 okt 2026, 07:41 UTC

   The funder published the call with a future closing date.

   Gewijzigd: status, notice type, published at (bronrecord Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02))

2. Voor het eerst gezien · 28 okt 2026, 21:22 UTC

   The funder announced the call. Applications have not opened yet.

   Bronrecord: Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02)

Elk gegeven op deze pagina komt uit de vermelding van de financier. Elke regel toont het record en het veld waaruit het is gelezen.

1. E1

   The funder is European Commission.

   Uit Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), veld /metadata/type/0, gelezen 29 okt 2026, 07:41 UTC · bron ↗ (opent in nieuw tabblad)

2. E2

   Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

   “2027-02-17T00:00:00.000+0000”

   Uit Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), veld /metadata/deadlineDate/0, gelezen 29 okt 2026, 07:41 UTC · bron ↗ (opent in nieuw tabblad)

3. E3

   The buyer describes the requirement in the notice.

   “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to d…”

   Uit Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), veld /metadata/descriptionByte/0, gelezen 29 okt 2026, 07:41 UTC · bron ↗ (opent in nieuw tabblad)

4. E4

   EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

   “EU call topic”

   Uit Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), veld /metadata/type/0, gelezen 29 okt 2026, 07:41 UTC · bron ↗ (opent in nieuw tabblad)

5. E5

   This is an EU call for proposals.

   “31094502”

   Uit Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), veld /metadata/status/0, gelezen 29 okt 2026, 07:41 UTC · bron ↗ (opent in nieuw tabblad)

6. E6

   Applications open on 29 Oct 2026.

   “2026-10-29T00:00:00.000+0000”

   Uit Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), veld /metadata/startDate/0, gelezen 29 okt 2026, 07:41 UTC · bron ↗ (opent in nieuw tabblad)

7. E7

   The Funding & Tenders Portal gives the status as open for submission.

   Uit Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), veld /metadata/status/0, gelezen 29 okt 2026, 07:41 UTC · bron ↗ (opent in nieuw tabblad)

8. E8

   The notice is titled "Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications".

   Uit Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), veld /metadata/title/0, gelezen 29 okt 2026, 07:41 UTC · bron ↗ (opent in nieuw tabblad)

9. E9

   The EU contribution per grant is up to EUR 11,000,000 (from EUR 3,000,000).

   Uit Personalised approaches to reduce risks from Adverse Drug Reactions due to admi… (ID HORIZON-HLTH-2027-01-CARE-02), veld /metadata/budgetOverview/0, gelezen 29 okt 2026, 07:41 UTC · bron ↗ (opent in nieuw tabblad)

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. Datalicentie: Creative Commons Attribution 4.0 (European Commission) ↗ (opent in nieuw tabblad). Persoonlijke contactgegevens uit aankondigingen worden niet bewaard of getoond.